



Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes Mellitus With Infliximab

<https://doi.org/10.2337/dc19-0908>

Beckey Trinh,¹ Marc Y. Donath,^{1,2} and Heinz Läubli^{2,3}

We report a case of a 53-year-old male patient with melanoma who was treated with combination immune checkpoint blockade (ICB) with ipilimumab and nivolumab. The patient had advanced disease with metastasis to the liver, lung, and lymph nodes. After two doses of ICB, the patient developed hypocalcemia as a result of an immune-mediated hypoparathyroidism that was treated with calcium and vitamin D substitution. In addition, the patient suffered from immune-related colitis that required treatment with corticosteroids and two doses of infliximab. Combination immunotherapy led to a metabolic complete remission of the melanoma. After tapering corticosteroids, the patient was continued on nivolumab for several weeks. No abnormalities of blood glucose were noted until then in an otherwise lean patient with a BMI of 19.6 kg/m². When the patient developed a seronegative oligoarthritis affecting the right knee and both ankles, he was treated with local corticosteroid injections, but no systemic corticosteroids were used. ICB was stopped. Several days later, the patient was seen for progressive fatigue. Laboratory testing showed a mild hyponatremia and a random blood glucose of 22.3 mmol/L. HbA_{1c} was 11.6% (103 mmol/mol), and C-peptide was 933 pmol/L. A mixed meal tolerance test (MMTT) revealed a mixed dysfunction, including impaired insulin

secretion and reduced peripheral insulin sensitivity. Autoantibodies against islet cells were positive. Despite peripheral insulin resistance, positive autoantibodies and impaired insulin secretion led to the diagnosis of an immune-mediated diabetes mellitus (DM) similar to a type 1 DM with mixed features of β -cell dysfunction and peripheral insulin resistance. Because CRP levels were low throughout the observation period, systemic inflammation as the main cause of the hyperglycemia was also unlikely. Treatment with insulin injections was begun. Initially, a daily average of 17 units insulin was required. Because the patient also developed a more active oligoarthritis, we started a therapy with infliximab to block tumor necrosis factor- α (TNF- α). Treatment with infliximab resulted in a reversal of β -cell dysfunction and insulin resistance, and insulin therapy could be stopped. Restaging of the patient 2 months after the last insulin injection and infliximab dose demonstrated an ongoing complete remission of his diabetes (Fig. 1).

We report the first successful treatment, to our knowledge, of an ICB-induced DM with infliximab. In this lean patient, insulin treatment could be stopped, and MMTT indicated a recovery of pancreatic β -cell function and peripheral insulin sensitivity with consecutive normalization of HbA_{1c}. The role of TNF- α in insulin resistance in rodents is well

established, while blockade of TNF- α in patients with type 1 DM has shown clinically meaningful results only in a specific case (1–3). DM as a result of ICB has been reported, and patients have required insulin replacement therapy that could not be interrupted (4), ruling out a spontaneous resolution of ICB-induced DM without anti-inflammatory agents. Our report of a remission following TNF- α blockade suggests that its etiology might be different than in type 1 DM and that TNF- α blockade with infliximab could be used to cure ICB-induced DM. This is of relevance because many patients undergoing ICB treatment for melanoma will have a long-lasting remission, and quality of life is therefore strongly influenced by side effects. It also indicates that some specific patient populations with DM may particularly benefit from anti-inflammatory treatments (5). Certainly, larger cohorts are needed to determine the success rate, but this report advocates for the use of infliximab in patients with ICB-induced DM to restore β -cell function and insulin sensitivity.

Duality of Interest. H.L. received travel grants and consultant fees from Bristol-Myers Squibb, Roche, and Merck Sharp & Dohme. No other potential conflicts of interest relevant to this article were reported.

¹Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland

²Department of Biomedicine, University Hospital Basel, Basel, Switzerland

³Division of Medical Oncology, University Hospital Basel, Basel, Switzerland

Corresponding author: Beckey Trinh, beckey.trinh@usb.ch

Received 6 May 2019 and accepted 23 June 2019

© 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.




Figure 1—Clinical course of ICB-induced DM. Shown are values over the time course after starting the immune checkpoint inhibitor therapy and the MMTT at different time points.

Author Contributions. B.T., M.Y.D., and H.L. acquired and analyzed data and wrote the manuscript. B.T. and H.L. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Mastrandrea L, Yu J, Behrens T, et al. Etarget treatment in children with new-onset

type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. *Diabetes Care* 2009;32:1244–1249

2. Timper K, Hruz P, Beglinger C, Donath MY. Infliximab in the treatment of Crohn disease and type 1 diabetes. *Diabetes Care* 2013;36:e90–e91

3. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α :

direct role in obesity-linked insulin resistance. *Science* 1993;259:87–91

4. Clotman K, Janssens K, Specenier P, Weets I, De Block CEM. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. *J Clin Endocrinol Metab* 2018;103:3144–3154

5. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. *Nat Rev Drug Discov* 2014;13:465–476